Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including complex robotic surgery, clinical trials and novel therapeutics such as precision medicine, CAR T-Cell Therapy and other forms of immunotherapy.
Lumpectomy for Breast Cancer with Attention to Cosmetic Results
As more women live with breast cancer, minimization of significant deformity in the breast after breast preservation is increasingly gaining attention. Shicha Kumar, MD, FACS, a surgical oncologist in the Stacy Goldstein Breast Cancer Center at Rutgers Cancer Institute of New Jersey and assistant professor of surgery at Rutgers Robert Wood Johnson Medical School, shares some insight about oncoplastic surgical techniques during Breast Cancer Awareness Month. Learn more
Detecting Neurocognitive Change in Pediatric Cancer Patients
Although cure rates for children with cancer are increasing, cancer treatments can cause permanent deterioration of brain functions leading to impairments in attention, concentration, memory and learning. With the aid of a $3.4 million, five-year National Institutes of Health grant (R01CA220568), Peter D. Cole, MD, chief of pediatric hematology/oncology and the Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology at Rutgers Cancer Institute of New Jersey, and colleagues are exploring an approach that would detect these changes among children with acute lymphoblastic leukemia early during treatment. Dr. Cole, who is a co-principal investigator on the study and a professor of pediatrics at Rutgers Robert Wood Johnson Medical School says the goal is to identify a subset of patients who would benefit from a behavioral intervention or treatment clinical trial. Learn more
Ride. Raise. Cure.
Celebrating 15 years of the Century for the Cure charity bike ride last month, riders, volunteers and supporters gathered in Warren Township to set off on routes of up to 100 miles – pedaling to fund cutting-edge research at Rutgers Cancer Institute of New Jersey. Scott and Aileen Glickman started the event as a small ride as a way to ‘give back’ to Rutgers Cancer Institute, where Mr. Glickman received care for stage 4 non-Hodgkin lymphoma. Since the ride’s inception, the event has raised nearly $3 million. If you weren’t able to join us this year, you still have until November 30 to support the effort.
Racial Disparities in Survival Outcomes Shown in Pediatric Hodgkin Lymphoma Patients
In what is believed to be the largest dataset study to date examining the role of race on survival outcomes for pediatric patients with Hodgkin lymphoma, investigators at Rutgers Cancer Institute of New Jersey have found that black patients have significantly worse overall survival at five years than white patients when accounting for all available clinical variables. The work was led by Rutgers Cancer Institute radiation oncologist Rahul Parikh, MD, who is the director of the Laurie Proton Therapy Center at Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, and an associate professor of radiation oncology at Rutgers Robert Wood Johnson Medical School. It was presented as part of an oral presentation at the Annual Meeting of the American Society for Radiation Oncology in Chicago last month.
